Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations

BACKGROUND: Clozapine is the only medication licenced for treating patients with treatment-refractory schizophrenia. However, there are no evidence-based guidelines as to the optimal plasma level of clozapine to aim for, and their association with clinical and functional outcome. OBJECTIVE: We asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Krivoy, Amir, Whiskey, Eromona, Webb-Wilson, Henrietta, Joyce, Dan, Tracy, Derek K., Gaughran, Fiona, MacCabe, James H., Shergill, Sukhwinder S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524694/
https://www.ncbi.nlm.nih.gov/pubmed/34676067
http://dx.doi.org/10.1177/20451253211037179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524694/
https://www.ncbi.nlm.nih.gov/pubmed/34676067
http://dx.doi.org/10.1177/20451253211037179

Ejemplares similares